Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $13M (up 0.1% year over year) with net income of −$79M.
Q2 2026 key financials · XBRL
- Revenue
- $13M
- +0.1% YoY · +24.9% QoQ
- Net income
- −$79M
- −16.1% YoY · +11.1% QoQ
- Operating margin
- -609.4%
- EPS (diluted)
- −$0.35
- +10.3% YoY · +12.5% QoQ
Source: XBRL data from the OCULAR THERAPEUTIX, INC (OCUL) Q2 2026 10-Q on SEC EDGAR. USD.
OCULAR THERAPEUTIX, INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $13.475M, up $16K YoY from $13.459M, including DEXTENZA product revenue $13.475M
- DEXTENZA net revenue up $80K YoY; gross-to-net provisions 55.0% vs 51.7%
- Operating loss $82.109M vs $67.641M; operating margin -609.3% vs -502.6%
- Net loss $78.763M vs $67.814M; research and development expense $54.138M
- Outlook: DEXTENZA growth from HOPD sales, offset by higher gross-to-net adjustments; AXPAXLI NDA submission expected fourth quarter 2026
Risk Factors
- No risk-factors section provided; supplied text contains Item 5, exhibits, and signatures only
- No newly added risk factor identifiable from the provided filing text
- No materially updated regulatory, legal, operational, competitive, market, or financial risk disclosed in the provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OCULAR THERAPEUTIX, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.